Patent Application: Detecting Pancreatic Cancer
Summary
The USPTO has published a patent application (US20260085360A1) detailing methods for detecting pancreatic cancer. The application describes a method involving measuring CA19-9 levels alongside other markers like OPN, MIA, and CEACAM-1 in a subject's sample.
What changed
This document is a published patent application from the USPTO, not a regulatory rule or guidance. It describes compositions and methods for detecting pancreatic cancer by measuring levels of CA19-9 polysaccharide and specific polynucleotide or polypeptide markers (OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP) relative to a reference. An increase in both CA19-9 and at least one other marker indicates the presence of pancreatic cancer.
As a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it may inform future research and development in diagnostic tools for pancreatic cancer, potentially impacting companies in the biotechnology and medical device sectors. Compliance officers should note this as a development in diagnostic technology rather than an immediate regulatory requirement.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR DETECTING PANCREATIC CANCER
Application US20260085360A1 Kind: A1 Mar 26, 2026
Inventors
Jin Song, Zhen Zhang, Daniel Wan-Yui Chan
Abstract
Provided herein are methods of detecting pancreatic cancer in a subject, the method comprising measuring in a sample from the subject a level of CA19-9 polysaccharide relative to a reference, and a level of a polynucleotide or polypeptide of at least one marker selected from the group consisting of: OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP relative to a reference, wherein an increased level of the CA19-9 polysaccharide relative to a reference and an increased level of the polynucleotide or polypeptide relative to a reference indicates presence of pancreatic cancer in the subject.
CPC Classifications
C12Q 1/6886 C07K 14/4748 G01N 33/57525 C12Q 2600/158
Filing Date
2025-07-24
Application No.
19279817
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.